Clinical Trial Update: Reduction or Discontinuation of CNI's With Conversion to Everolimus-Based Immunosuppresion [Phase 4]

View source ↗

Summary

This Phase 4 study evaluates reducing or stopping calcineurin inhibitors by converting kidney transplant recipients to everolimus-based immunosuppression.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Transplantation

Drugs mentioned

• Everolimus (everolimus)

Snippet

Sponsor: Rabin Medical Center | Conditions: Kidney Diseases | Phase 4 | Status: UNKNOWN